1. Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery 
Alan F Merry, FANZCA, Peter J Raudkivi, FRACS, Neil G Middleton, FCASA, John M McDougall, FRCA, Parma Nand, FRACS, Brigid P Mills, MHSc, Bruce J Webber, MHSc, Chris M Frampton, PhD, Harvey D White, DSc 
The Annals of Thoracic Surgery 
Volume 77, Issue 3, Pages (March 2004)
DOI: /j.athoracsur

2. Fig 1 Trial profile. (ITT = intent to treat.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )

3. Fig 2
Activated clotting time (ACT; mean, SE) by study drug. (Heavy line = bivalirudin; light line = heparin plus protamine.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )

4. Fig 3
Perioperative blood loss: box plots showing the median, interquartile range, range, and outliers. The top two outliers in the bivalirudin group relate to patients who were converted to cardiopulmonary bypass and administered heparin.
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )

5. Fig 4
Graft flow by patient at 3 months: box plots showing the median, interquartile range, range, and outliers. The median graft flow grades were 3.0 (bivalirudin) and 2.67 (heparin): Mann-Whitney test, p =
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )

6. Fig 5
Mean graft flow by patient: the proportion of patients with no impaired grafts was higher in the bivalirudin group: χ2 test, p = Hatched bars = bivalirudin (n = 40); open bars = heparin plus protamine (n = 39).
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )